Stifel Nicolaus initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS Get Rating) in a research note released on Monday, The Fly reports. The brokerage issued a buy rating and a $102.00 price objective on the stock. KRYS has been the subject of a number of other reports. HC Wainwright ...

Krystal Biotech, Inc. (NASDAQ:KRYS Get Rating) Director Dino A. Rossi sold 40,000 shares of the businesss stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total value of $3,330,000.00. Following the transaction, the director ...

PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the43rd Annual TD Cowen Health ...

B-VEC PDUFA date May 19, 2023 Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine Four pipeline clinical trials in dermatology, respiratory and aesthetics to initiate in 2023 Strong balance sheet, closing the ...

NEW PDUFA DATE OF MAY 19, 2023PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration(FDA) notified the Company that based on manufacturing information submitted to the Agency on ...